Statin therapy appears to increase the risk for type 2 diabetes by 46%,
even after adjustment for confounding factors, a large new
population-based study concludes.
This suggests a higher risk for diabetes with statins in the general
population than has previously been reported, which has been in the
region of a 10% to 22% increased risk, report the researchers, led by
Henna Cederberg, MD, PhD, from the University of Eastern Finland and
Kuopio University Hospital, and colleagues, who
published their study online March 4 in
Diabetologia.
The majority of people in this new study were taking atorvastatin and
simvastatin, and the risk for diabetes was dose-dependent for these two
agents, the researchers found.
Nevertheless, senior author Markku Laakso, MD, from the University of Eastern Finland and Kuopio University Hospital, told Medscape Medical News:
"Even if statin treatment is increasing the risk of getting diabetes,
statins are very effective in reducing cardiovascular risk.
"Therefore I wouldn't make a conclusion from my study that people should
stop statin treatment, especially those patients who have a history of
myocardial infarction or so on.
"But what I would say is that people who are at the higher risk, if they
are obese, if they have diabetes in the family, etc, should try to
lower their statin dose, if possible, because high-dose statin treatment
increases the risk vs lower-dose statin treatment," he continued.
Asked to comment, Alvin C Powers, MD, from Vanderbilt University School
of Medicine, Nashville, Tennessee, explained that there were limitations
to the conclusions that could be drawn from this study.
Speaking as part of the Endocrine Society, he said: "The first thing is
that this study did not examine the benefits of statin therapy, it
examined only the risk of diabetes."
With every treatment, there are risks and benefits, and the benefits of
statins have been clearly proven in certain situations. In those
instances, "the benefit would outweigh the increased risk of diabetes
for many people," Dr Powers told Medscape Medical News.
Statins Appear to Affect Insulin Secretion and Sensitivity
Dr Cederberg and colleagues explain that previous studies have suggested
an increased risk of developing diabetes, of varying levels, associated
with statin use. However, in many of these, study populations have been
selective, especially in statin trials, which have included
participants at high risk for cardiovascular disease.
Hence, the risk for diabetes in clinical trials is likely to differ from
that in the general population. And very often, in previous studies the
diagnosis of diabetes has been based on self-reported diabetes or
fasting glucose measurement, leading to an underestimation of the actual
numbers of incident diabetes cases.
In this new study, the authors investigated the effects of statin
treatment on blood glucose control and the risk for type 2 diabetes in
8749 nondiabetic men age 45 to 73 years in a 6-year follow-up of the
population-based
Metabolic Syndrome in Men (METSIM) trial, based in Kuopio, Finland.
The authors also investigated the mechanisms of statin-induced diabetes
by evaluating changes in insulin resistance and insulin secretion.
Diabetes was diagnosed via an oral glucose tolerance test (OGTT), HbA1c levels
≥ 6.5% (48 mmol/mol) or by having started glucose-lowering medication.
During the follow-up, 625 of the participants were diagnosed with
diabetes. OGTT-derived indices were used to assess insulin sensitivity
and secretion.
Statins were taken by 2412 individuals. The drugs were associated with
an increased risk for type 2 diabetes even after adjustment for age,
body mass index, waist circumference, physical activity, smoking,
alcohol intake, family history of diabetes, and beta-blocker and
diuretic treatment, at a hazard ratio (HR) of 1.46.
The risk was found to be dose-dependent for simvastatin and
atorvastatin, which were taken by 388 and 1409 participants,
respectively. High-dose simvastatin was associated with a hazard ratio
(HR) of 1.44 for diabetes vs 1.28 for low-dose therapy, while the HR for
diabetes with high-dose atorvastatin was 1.37.
Statin therapy was also associated with a significant increase in 2-hour glucose (P = .001) and the glucose area under the curve at follow-up ( P < .001), as well as a nominally significant increase in fasting plasma glucose (P = .037).
Furthermore, individuals taking statins had a 24% decrease in insulin
sensitivity and a 12% reduction in insulin secretion compared with those
not receiving the drugs. These increases were again dose-dependent for
atorvastatin and simvastatin.
Although pravastatin, fluvastatin, and lovastatin were found to be less
diabetogenic than atorvastatin and simvastatin, the number of
participants taking these agents was too small to reliably estimate
their individual effects on the risk for diabetes, the research team
notes.
Which Patients Should Take Statins?
Discussing the take-home message for prescribers seeking to balance the
risk for diabetes with the benefits of statin therapy, Dr Laasko
reiterated that individuals with a history of cardiovascular events and
high LDL cholesterol "should definitely take statins."
However, he emphasized that the main aim of statins is to prevent a
recurrent cardiovascular event, so individuals need to have had one
event to start statin therapy.
"But in primary prevention, especially in women, who are at a lower risk
of getting cardiovascular disease, maybe we should be more careful when
we start statin treatment?" he ventured. "Statins are not meant to be a
treatment for everybody."
Dr Powers observed that this new study doesn't provide any information
about whether people who have diabetes who are on a statin should
continue with the statin, "but there are clear benefits for statin
therapy in people who have diabetes.
"People who have diabetes who are on a statin should continue with the
statin.…This increased risk of diabetes, to me, is not relevant to their
reason for taking the statin," he commented.
And in diabetes patients who have heart disease and are taking a statin,
"the risk/benefit ratio would clearly be in the direction of benefit,"
Dr Powers observed.
In individuals who do not have diabetes and who are taking a statin, for
example to reduce their risk for cardiovascular disease, "statin
therapy has to be considered in the context of what's the benefit of the
statin therapy in that group…especially in individuals who are
genetically susceptible to type 2 diabetes or who have prediabetes," he
continued.
"Those individuals will need to be monitored for the development of diabetes."
"People who are taking statins should keep taking statins, if there's an
appropriate reason for them taking a statin. The risk/benefit ratio in
most people is in favor of benefit; the risk is outweighed by that
benefit," he concluded.
This work has been supported by the Academy of Finland, the Finnish
Diabetes Research Foundation, the Finnish Cardiovascular Research
Foundation, the Strategic Research Funding from the University of
Eastern Finland, Kuopio, and a grant from Kuopio University Hospital.
The authors have reported no relevant financial relationships.
